✦ LIBER ✦

Phase I/IB Study of Polyadenylic-Polyuridylic Acid in Patients with Advanced Malignancies: Clinical and Biologic Effects

✍ Scribed by WITT, PATRICIA L.; ZAHIR, S.; RITCH, PAUL S.; McAULIFFE, TIMOTHY M.; EWEL, CYNTHIA H.; BORDEN, ERNEST C.

Book ID: 120645218
Publisher: Mary Ann Liebert
Year: 1996
Tongue: English
Weight: 790 KB
Volume: 16
Category: Article
ISSN: 1079-9907
DOI: 10.1089/jir.1996.16.631

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I toxicity and pharmacology study

Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies

✍ Eddie Hu; Richard Ko; Robert Koda; Peter Rosen; Susan Jeffers; Mark Scholtz; Fra 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 466 KB

Phase I Study of Doxil® and Vinorelbine

Phase I Study of Doxil® and Vinorelbine in Patients with Advanced Malignancies

✍ Laufman, Leslie R.; Spiridonidis, C. Harris; Jones, Jacqueline J.; Rhodes, Virgi 📂 Article 📅 2004 🏛 Informa plc 🌐 English ⚖ 124 KB

A phase I study of sirolimus and bevaciz

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies

✍ E.E.W. Cohen; M.R. Sharma; L. Janisch; M. Llobrera; L. House; K. Wu; J. Ramirez; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 193 KB

Phase I combination study of trabectedin

Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies

✍ Lia Gore, E. Rivera, M. Basche, S. L. Moulder-Thompson, J. Li, S. Eppers, S. Gro 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 159 KB

A phase I pharmacological and biological

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

✍ Laura Q. M. Chow; Daniel L. Gustafson; Cindy L. O’Bryant; Lia Gore; Michele Basc 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 425 KB

Phase I study of pegylated liposomal dox

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie